Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Latent Labs has developed advanced generative AI models that enable the de novo computational creation of novel proteins—such as antibodies and enzymes—for use in drug discovery, protein engineering, and synthetic biology. The company operates a partnership-driven model rather than developing its own therapeutics pipeline. It recently emerged from stealth with $50M in funding to commercialize its programmable biology platform for biotech/pharma partners. No direct clinical programs or results have been disclosed yet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Latent Labs.